Current as of December 10, 2023
Protocol 86-EI-0062 began as a randomized, double-masked, placebo controlled study to evaluate the efficacy and safety of 0.5% topical cysteamine but was subsequently amended as a natural history protocol. Additional protocols conducted at the National Eye Institute (NEI) at the National Institutes of Health (NIH) began after this protocol and tested various formulations of cysteamine topical solution for efficacy and safety in patients with cystinosis. Subjects from these NIH protocols testing various formulations were ultimately transferred to this natural history protocol for open-label ...
- INCLUSION CRITERIA:
- Patients must have a documented clinical diagnosis of cystinosis.
- Patients should be 2 years old or older.
- EXCLUSION CRITERIA:
- Inability to travel to NIH for a baseline examination, after 1 year, and every two years thereafter for follow-up
- Inability to cooperate for slit-lamp examination
The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
Any Time Point up to 27 Years
All reviews come from applied patients